AMP celebrates SCOTUS decision on AMP v. Myriad Case

June 13, 2013

Bethesda, MD, June 13, 2013: Today, the United States Supreme Court released its landmark decision in Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al. The Court unanimously agreed that "A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patentable because it is not naturally occurring."1

The decision helps to lay the foundation for continued research and application of diagnosis and treatment of diseases at the molecular level. "AMP applauds the U.S. Supreme Court on their ground breaking, unanimous decision. There is no question that this is a critical and right decision for the future of medicine and science. Biomedical researchers, clinicians, and most importantly patients will see great benefit from this development," said Jennifer L. Hunt, MD, MEd, AMP President.

In supporting AMP's position, the Court's detailed ruling noted, "In this case... Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention."2 "We believe the High Court today removed a significant barrier to innovation in molecular pathology testing," said Roger D. Klein, MD, JD, AMP Professional Relations Committee Chair," and we look forward to future advancements in clinical diagnostics and therapeutics that will accrue to the benefit of our patients and our field."
-end-
AMP and its members look forward to continuing their efforts to transform healthcare through their molecular pathology expertise and their work in precision medicine. The Court's decision can be found online at http://www.supremecourt.gov/opinions/12pdf/12-398_8njq.pdf.

1, 2 Association for Molecular Pathology et al v. Myriad Genetics, Inc. et al, No. 12-398, U.S. (2013)

ABOUT AMP:

The Association for Molecular Pathology (AMP) is an international medical professional association dedicated to the advancement, practice, and science of clinical molecular laboratory medicine and translational research based on the applications of molecular biology, genetics, and genomics. For more information, please visit http://www.amp.org.

CONTACT:

Catherine Davidge
301-634-7400
cdavidge@amp.org

Association for Molecular Pathology

Related Molecular Pathology Articles from Brightsurf:

Aging alone does not explain kidney pathology
Histopathology in non-neoplastic kidney tissue from 1,347 nephrectomy specimens showed very limited histopathologic changes in subset of older individuals.

MarrowQuant: A new digital-pathology tool
EPFL scientists have developed a digital pathology tool for quantifying bone marrow compartments in standard histological sections.

Novel pathology could improve diagnosis and treatment of Huntington's and other diseases
Bristol scientists have discovered a novel pathology that occurs in several human neurodegenerative diseases, including Huntington's disease.

Framework helps clinicians identify serious spinal pathology
Rehabilitation clinicians and other health care professionals now have a framework for assessing and managing people who may have serious spinal pathologies.

Subtle decline in cognition predicts progression to Alzheimer's pathology
Researchers at UC San Diego School of Medicine report that abnormal levels of beta-amyloid plaques in brain predict cognitive decline and higher risk of developing Alzheimer's disease, but also that cognitive performance predicts progression from normal to abnormal levels of beta-amyloid.

Standard pathology tests outperform molecular subtyping in bladder cancer
While trying to develop a comparatively easy, inexpensive way to give physicians and their patients with bladder cancer a better idea of likely outcome and best treatment options, scientists found that sophisticated new subtyping techniques designed to do this provide no better information than long-standing pathology tests.

Metabolic disturbance in the brain exacerbates, may forewarn Alzheimer's pathology
A better understanding of the metabolic processes in the brain -- specifically disturbances resulting from neurodegenerative diseases -- has important implications for potential treatments.

Association for Molecular Pathology expresses serious concerns with Congress' attempt to resurrect human gene patenting debate and reverse settled Supreme Court ruling
AMP has expressed serious concerns with Congress' recent proposal to amend Section 101 of the Patent Act.

Brain cell genomics reveals molecular pathology of autism
Molecular changes in specific types of neural cells and brain circuits correlate with the clinical severity of autism spectrum disorder, a new single-cell analysis of brain cells from autism patients finds.

Improved understanding of the pathology of dwarfism may lead to new treatment targets
Pseudoachondroplasia (PSACH) is a severe inherited dwarfing condition In PSACH, a genetic mutation leads to abnormal retention of cartilage oligomeric matrix protein (COMP) within the endoplasmic reticulum (ER) of cartilage-producing cells (chondrocytes), which interferes with function and cell viability.

Read More: Molecular Pathology News and Molecular Pathology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.